Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Epilepsy
Interventions
DRUG

Retigabine IR

Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).

Trial Locations (66)

1113

GSK Investigational Site, Sofia

1431

GSK Investigational Site, Sofia

2100

GSK Investigational Site, Koebenhavn Oe

2600

GSK Investigational Site, Glostrup Municipality

3000

GSK Investigational Site, Leuven

4000

GSK Investigational Site, Liège

GSK Investigational Site, Plovdiv

4293

GSK Investigational Site, Dianalund

5800

GSK Investigational Site, Pleven

9000

GSK Investigational Site, Ghent

10400

GSK Investigational Site, Bangkok

13509

GSK Investigational Site, Berlin

16153

GSK Investigational Site, Genoa

24105

GSK Investigational Site, Kiel

28046

GSK Investigational Site, Madrid

33617

GSK Investigational Site, Bielefeld

35033

GSK Investigational Site, Rennes

35043

GSK Investigational Site, Marburg

36204

GSK Investigational Site, Vigo

40002

GSK Investigational Site, Khon Kaen

40139

GSK Investigational Site, Bologna

41009

GSK Investigational Site, Seville

46026

GSK Investigational Site, Valencia

49005

GSK Investigational Site, Dnipro

53100

GSK Investigational Site, Siena

53105

GSK Investigational Site, Bonn

54035

GSK Investigational Site, Nancy

56126

GSK Investigational Site, Pisa

59037

GSK Investigational Site, Lille

60126

GSK Investigational Site, Torrette Di Ancona

61068

GSK Investigational Site, Kharkiv

65014

GSK Investigational Site, Odesa

67098

GSK Investigational Site, Strasbourg

67513

GSK Investigational Site, Oleksandrivka Village, Odesa

69677

GSK Investigational Site, Lyon

70372

GSK Investigational Site, Stuttgart

71100

GSK Investigational Site, Foggia

72076

GSK Investigational Site, Tübingen

77694

GSK Investigational Site, Kehl-Kork

79010

GSK Investigational Site, Lviv

83037

GSK Investigational Site, Donetsk

87042

GSK Investigational Site, Limoges

89100

GSK Investigational Site, Reggio Calabria

90110

GSK Investigational Site, Songkhla

90129

GSK Investigational Site, Palermo

91045

GSK Investigational Site, Luhansk

107150

GSK Investigational Site, Moscow

117049

GSK Investigational Site, Moscow

193019

GSK Investigational Site, Saint Petersburg

308007

GSK Investigational Site, Belgorod

350007

GSK Investigational Site, Krasnodar

420064

GSK Investigational Site, Kazan'

443095

GSK Investigational Site, Samara

00163

GSK Investigational Site, Rome

00185

GSK Investigational Site, Rome

4818 CK

GSK Investigational Site, Breda

2103 SW

GSK Investigational Site, Heemstede

5591 VE

GSK Investigational Site, Heeze

2512 VA

GSK Investigational Site, The Hague

13-300

GSK Investigational Site, Iława

40-662

GSK Investigational Site, Katowice

31-209 Krakow

GSK Investigational Site, Krakow

00-453

GSK Investigational Site, Warsaw

02-952

GSK Investigational Site, Warsaw

214 019

GSK Investigational Site, Smolensk

Unknown

GSK Investigational Site, Poltava

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01227902 - Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures | Biotech Hunter | Biotech Hunter